<DOC>
	<DOCNO>NCT01153893</DOCNO>
	<brief_summary>The purpose trial ass safety , reactogenicity immunogenicity GSK Biologicals ' pneumococcal conjugate vaccine GSK1024850A administer either booster dose two dose catch-up vaccination second year life Nigerian subject previously enrol primary vaccination study NCT00678301 . This protocol post deal objective &amp; outcome measure booster phase . The objective &amp; outcome measure primary phase present separate protocol posting ( NCT number = NCT00678301 ) .</brief_summary>
	<brief_title>Immunization Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A Unprimed Children Nigeria</brief_title>
	<detailed_description />
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Subjects investigator believe parent ( ) /Legally Acceptable Representative ( ) ( LAR ( ) ) comply requirement protocol . A male female , include 1521 month age time visit 1 . For PnPn group , subject complete full vaccination course study NCT00678301 . For ZilPn group , subject previously enrol control group study NCT00678301 . Written informed consent , sign thumb print , obtain parent ( ) /LAR ( ) subject . Where parent ( ) /LAR ( ) illiterate , consent form countersign witness . Healthy subject establish medical history clinical examination enter study . Use investigational nonregistered product study vaccine ( ) /product ( ) within 30 day precede first dose vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior vaccination . Planned administration/administration vaccine foreseen study protocol period start 30 day dose study vaccine end 30 day . Locally recommended vaccine example Oral Polio Vaccine influenza vaccine always allow , even concomitantly administer study vaccine , document CRF . Concurrently participate another clinical study time study period , subject expose investigational noninvestigational product . Administration pneumococcal vaccine since end study NCT00678301 . Any confirm suspected immunosuppressive immunodeficient condition , since end study NCT00678301 , base medical history physical examination . Major congenital defect serious chronic illness . History progressive neurological disorder seizure . Acute disease and/or fever time enrolment . History reaction hypersensitivity likely exacerbate component vaccine . Administration immunoglobulins and/or blood product less 3 month prior visit 1 plan use study . Child care .</criteria>
	<gender>All</gender>
	<minimum_age>15 Months</minimum_age>
	<maximum_age>21 Months</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Pneumococcal disease</keyword>
	<keyword>Pneumococcal vaccine</keyword>
	<keyword>Catch-up vaccination</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Booster vaccination</keyword>
	<keyword>Safety</keyword>
</DOC>